Top Markets
Coin of the day
Wuhan Hiteck Biological Pharma Co.,Ltd Wuhan Hiteck Biological Pharma Co.,Ltd

Wuhan Hiteck Biological Pharma Co.,Ltd

300683
Rang în acțiuni #13466
Wuhan Hiteck Biological Pharma Co.,Ltd is a biopharmaceutical enterprise... Wuhan Hiteck Biological Pharma Co.,Ltd is a biopharmaceutical enterprise operating in China, primarily engaged in the research, development, manufacturing, and commercialization of bio-engineered products and lyophilized injectable medications. The company's extensive product portfolio encompasses a variety of pharmaceutical solutions, such as Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye acyclovir tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository; Xunkeyuan tinidazole suppository; and Shufu nimodipine sustained-release tablets. Beyond therapeutics, Wuhan Hiteck also provides a comprehensive array of diagnostic kits. These include tests for measles virus and rubella virus nucleic acid, mycoplasma isolation and identification, bacterial vaginosis rapid detection, measles virus IgG antibodies, and the coronavirus N-protein. Furthermore, the firm supplies active pharmaceutical ingredients (APIs) and their chemical intermediates, notably Lopinavir and Ritonavir. Its core therapeutic areas of focus are the nervous system and oncology. Established in 1992, Wuhan Hiteck Biological Pharma Co.,Ltd is headquartered in Wuhan, China.
Preț acțiune
$3.71
Capitalizare de piață
$486.16M
Schimbare (1 zi)
-0.97%
Schimbare (1 an)
-45.64%
Țară
CN
Tranzacționează Wuhan Hiteck Biological Pharma Co.,Ltd (300683)

Categorie

Raport P/S pentru Wuhan Hiteck Biological Pharma Co.,Ltd (300683)
Raport P/S la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Wuhan Hiteck Biological Pharma Co.,Ltd, raportul P/S actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/S de 0.
Istoricul raportului P/S pentru Wuhan Hiteck Biological Pharma Co.,Ltd din 2026 până în 2026
Raport P/S la sfârșitul fiecărui an
An Raport P/S Schimbă
Nu sunt suficiente date pentru perioada selectată.
Raport P/S pentru companii similare sau competitoare